INmune Bio announces presentations on Alzheimer’s research at the upcoming CTAD conference in San Diego, December 2025.
Quiver AI Summary
INmune Bio, Inc., a clinical-stage biotechnology company specializing in inflammation and immunology, announced its participation in the 18th Clinical Trials on Alzheimer’s Disease conference in San Diego from December 1-4, 2025. The company will present two studies: one on XPro1595, a selective TNF neutralizer in early Alzheimer's patients, and another on the Early Mild Alzheimer’s Cognitive Composite related to blood-based biomarkers. INmune Bio is advancing several therapeutic platforms, including treatments targeting tumor necrosis factor, umbilical cord-derived mesenchymal stromal cells, and enhancing natural killer cell activity for cancer patients. The press release includes forward-looking statements regarding clinical trials and the potential for regulatory approval, emphasizing risks and uncertainties inherent in drug development.
Potential Positives
- INmune Bio is presenting research on XPro1595, a selective soluble TNF neutralizer, at a significant Alzheimer's conference, indicating progress in their clinical development efforts.
- The company is participating in the 18th Clinical Trials on Alzheimer’s Disease conference, which highlights its involvement in important discussions within the field of Alzheimer's research.
- Two research presentations indicate active engagement in clinical trials and contribute to the company's visibility in the biopharmaceutical industry.
- The focus on early Alzheimer's treatments aligns with growing market needs, potentially positioning INmune Bio favorably for future investment and growth opportunities.
Potential Negatives
- Clinical trials are still in early stages, indicating uncertain outcomes and potentially limited progress in product development.
- Products mentioned in the press release have not received FDA approval, raising concerns about their viability and market potential.
- The company highlights significant risks and uncertainties that could adversely affect its business operations and ability to conduct research and development.
FAQ
What is the focus of INmune Bio, Inc.?
INmune Bio, Inc. focuses on developing treatments targeting inflammation and immunology.
Where will INmune Bio present at the CTAD conference?
INmune Bio will present in San Diego, CA, at the upcoming CTAD conference from December 1-4, 2025.
What are the titles of the presentations by INmune Bio?
The presentations are "XPro1595 in Early Alzheimer’s Disease" and "Validation of the Early Mild Alzheimer’s Cognitive Composite."
Who are the presenting authors for INmune Bio's presentations?
Kim A. Staats, PhD, and Sarah Barnum, PhD, will present at the conference.
What are the potential risks associated with INmune Bio's clinical trials?
Risks include uncertainties in achieving trial results, funding availability, and regulatory approvals.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INMB Hedge Fund Activity
We have seen 35 institutional investors add shares of $INMB stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRAETORIAN PR LLC removed 865,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,998,150
- UBS GROUP AG removed 293,699 shares (-65.4%) from their portfolio in Q3 2025, for an estimated $607,956
- DAUNTLESS INVESTMENT GROUP, LLC removed 248,542 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $514,481
- GATEPASS CAPITAL, LLC removed 235,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $542,850
- RHENMAN & PARTNERS ASSET MANAGEMENT AB removed 178,284 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $369,047
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 137,009 shares (+686.9%) to their portfolio in Q3 2025, for an estimated $283,608
- CITADEL ADVISORS LLC removed 101,511 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $234,490
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$INMB Analyst Ratings
Wall Street analysts have issued reports on $INMB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 07/02/2025
- Scotiabank issued a "Sector Underperform" rating on 07/01/2025
To track analyst ratings and price targets for $INMB, check out Quiver Quantitative's $INMB forecast page.
$INMB Price Targets
Multiple analysts have issued price targets for $INMB recently. We have seen 2 analysts offer price targets for $INMB in the last 6 months, with a median target of $4.3.
Here are some recent targets:
- Jason McCarthy from Maxim Group set a target price of $8.0 on 07/02/2025
- George Farmer from Scotiabank set a target price of $0.6 on 07/01/2025
Full Release
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.
Presentations:
| Title: | XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial |
| Date: | Monday, December 1, until Tuesday December 2, 2025 |
| Time: | 3:30pm (December 1 st ) – 5:30pm (December 2 nd ) PT |
| Location: | P057 |
| Presenting author: | Kim A. Staats, PhD. INmune Bio. |
| Title: | Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease |
| Date: | Thursday, December 4, 2025 |
| Time: | 7:15am - 5:00pm PT |
| Location: | P316 |
| Presenting author: | Sarah Barnum, PhD. Cognition Metrics. |
About INmune Bio Inc.
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target immunology and inflammation. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. The second program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. The third program, INKmune®, is designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
[email protected]
Daniel Carlson
Head of Investor Relations
(415) 509-4590
[email protected]
